PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10311653

Evaluating technology under changing financing arrangements.

B R Luce
View original source ↗Export metadata ↓

Abstract

Changes in health care financing, such as Medicare prospective pricing and Medicaid capitated payment programs, have encouraged medical product industries to provide evidence of new technologies' cost-effectiveness. Health care providers have an equal responsibility to determine the validity of that research.

Explore related subjects

Cost-Benefit AnalysisDrug IndustryIndustrySocietiesTechnology Assessment, BiomedicalUnited StatesJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B R Luce. 1986. Evaluating technology under changing financing arrangements.. https://pubmed.ncbi.nlm.nih.gov/10311653/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2000

['Medical technology assessment'; more than just efficacy].

'Medical technology assessment' means investigating the developments, costs and effects of medical technologies. Practising physicians increasingly are confronted with consequences of management based on such research results. In order to follow and participate in the discussion they should be aware of this and know the jargon. In policy problems, measures of effect in natural units (e.g. cardiovascular mortality) offer advantages over measures of clinical findings (e.g. decrease of the serum cholesterol levels). Survival in various health states and disorders can be compared by multiplying the number of life years gained by a factor for the quality of life in those years. Costs are usually expressed in monetary terms. These may be calculated as direct medical costs on the basis of fees or actual costs for society. The latter is the case when the balancing is based on a societal perspective. The societal perspective enables a more objective assessment of health effects than when a patient perspective is used. 'Incremental cost effectiveness' expresses where extra expenditures will have maximum effect, and bears higher relevance for policy decisions than mean costs per unit of effect. Immaterial matters are more difficult to assess, but should nevertheless be considered in selecting the policy to be implemented.

Cost-Benefit Analysis↗